Wang Peijian, Gao Beiyao, Wang Siyuan, Wang Zhao, Zhao Li, Duan Yajing, Ge Lijun, Jiang Shan, Chen Wenhui
Department of Rehabilitation Medicine, China-Japan Friendship Hospital, Beijing, China.
National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
J Thorac Dis. 2024 Sep 30;16(9):5727-5741. doi: 10.21037/jtd-24-568. Epub 2024 Sep 19.
Lung transplantation (LTx) is a well-established option for patients in the end-stage of lung disease that is not responsive to other treatments. Although the survival rate after LTx has seen a significant increase, exercise tolerance is still limited and poses a big obstacle to recovery after LTx. Pulmonary rehabilitation (PR) is a comprehensive intervention that has many benefits for patients with chronic respiratory disease. However, the effectiveness of PR on adult patients with LTx is inconclusive. We performed this meta-analysis to assess the efficacy of PR in adult LTx recipients.
Eligible randomized controlled trials (RCTs) and quasi-experimental studies published until March 25, 2024 were searched in MEDLINE, Embase, Web of Science and CINAHL. Additionally, reference lists and published systematic reviews were scanned by manual searching. Studies selection, data extraction, and risk of bias assessment were conducted independently. Stata software (version 17.0) was utilized.
There were 21 studies (9 RCTs and 12 quasi-experimental studies) were identified. Pooled analysis showed that PR positive effect in improving 6-minute walking distance (6MWD) [standard mean difference (SMD) =1.28, 95% confidence interval (CI): 1.05-1.50, P<0.001], maximum oxygen consumption (VOmax) (SMD =0.42, 95% CI: 0.15-0.68, P=0.002), handgrip force (HGF) (SMD =0.49, 95% CI: 0.26-0.73, P<0.001), and quadriceps force (QF) (SMD =0.63, 95% CI: 0.45-0.82, P<0.001). There was no significant publication bias in those outcomes mentioned above.
PR shows evidence for being an effective adjunctive strategy for improving exercise capacity after LTx, but multi-center trials on larger populations are required to confirm its clinical benefits in the real-world setting.
肺移植(LTx)是终末期肺部疾病患者经其他治疗无效后的一种成熟治疗选择。尽管肺移植后的生存率显著提高,但运动耐量仍然有限,这对肺移植后的恢复构成了重大障碍。肺康复(PR)是一种综合干预措施,对慢性呼吸系统疾病患者有诸多益处。然而,PR对成年肺移植患者的有效性尚无定论。我们进行了这项荟萃分析,以评估PR对成年肺移植受者的疗效。
在MEDLINE、Embase、Web of Science和CINAHL中检索截至2024年3月25日发表的符合条件的随机对照试验(RCT)和准实验研究。此外,通过手动检索扫描参考文献列表和已发表的系统评价。研究选择、数据提取和偏倚风险评估均独立进行。使用Stata软件(版本17.0)。
共纳入21项研究(9项RCT和12项准实验研究)。汇总分析表明,PR在改善6分钟步行距离(6MWD)[标准平均差(SMD)=1.28,95%置信区间(CI):1.05 - 1.50,P<0.001]、最大耗氧量(VOmax)(SMD =0.42,95%CI:0.15 - 0.68,P =0.002)、握力(HGF)(SMD =0.49,95%CI:0.26 - 0.73,P<0.001)和股四头肌力量(QF)(SMD =0.63,95%CI:0.45 - 0.82,P<0.001)方面有积极作用。上述结果不存在显著的发表偏倚。
PR显示出是改善肺移植后运动能力的有效辅助策略的证据,但需要在更大规模人群上进行多中心试验,以证实其在实际临床环境中的益处。